Scandion Oncology A/S reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was DKK 8.77 million compared to DKK 23.02 million a year ago. Basic loss per share from continuing operations was DKK 0.22 compared to DKK 0.72 a year ago. Diluted loss per share from continuing operations was DKK 0.22 compared to DKK 0.72 a year ago.
For the six months, net loss was DKK 18.06 million compared to DKK 35.94 million a year ago.